Valeant Pharmaceuticals International, Inc. operates as a multinational, specialty pharmaceutical, and medical device company that develops, manufactures, and markets a range of pharmaceuticals, over-the-counter (OTC) products, and medical devices. The company operates through three segments: Bausch + Lomb/International, Branded Rx, and U.S. Diversified Products. The Bausch + Lomb/International segment provides pharmaceutical products, OTC products, and medical device products, primarily consist of Bausch + Lomb products, with a focus on the vision care, surgical, consumer, and ophthalmology Rx products in the United States; and pharmaceutical products, generic pharmaceutical products, OTC products, medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia and New Zealand, Latin America, Africa, and the Middle East. The Branded Rx segment sells gastrointestinal and dermatological products in the United States. The U.S. Diversified Products segment offers pharmaceutical products, OTC products, and medical device products in the areas of neurology and certain other therapeutic classes, including aesthetics. The company was founded in 1983 and is headquartered in Laval, Canada.
Industry, Sector and Symbol
Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
Phone+1-514-7446792
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
OptionableOptionable
Valeant Pharmaceuticals Intl (TSE:VRX) Frequently Asked Questions
What is Valeant Pharmaceuticals Intl's stock symbol?
Valeant Pharmaceuticals Intl trades on the Toronto Stock Exchange (TSX) under the ticker symbol "VRX."
What price target have analysts set for VRX?
1 brokerages have issued 1-year target prices for Valeant Pharmaceuticals Intl's shares. Their predictions range from C$25.00 to C$25.00. On average, they expect Valeant Pharmaceuticals Intl's share price to reach C$25.00 in the next twelve months. View Analyst Price Targets for Valeant Pharmaceuticals Intl.
What is the consensus analysts' recommendation for Valeant Pharmaceuticals Intl?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Valeant Pharmaceuticals Intl in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Valeant Pharmaceuticals Intl.
Has Valeant Pharmaceuticals Intl been receiving favorable news coverage?
Media stories about VRX stock have been trending very positive on Tuesday, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Valeant Pharmaceuticals Intl earned a media sentiment score of 3.2 on InfoTrie's scale. They also assigned news stories about the specialty pharmaceutical company a news buzz of 4.0 out of 10, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next several days.
Who are some of Valeant Pharmaceuticals Intl's key competitors?
Some companies that are related to Valeant Pharmaceuticals Intl include Acerus Pharmaceuticals (ASP), Aequus Pharmaceuticals (AQS), Amryt Pharma (AMYT), Aphria (APH), Aurora Cannabis (ACB), Bausch Health Companies (BHC), Benchmark (BMK), Biosyent (RX), Cannabis Science (CBIS), Cannpal Animal Therapeutics (CP1), Canopy Growth (WEED), Charlotte's Web (CWBHF), Choom (CHOOF), Cipher Pharmaceuticals (CPHRF) and Cipher Pharmaceuticals (CPH).
Who are Valeant Pharmaceuticals Intl's key executives?
Valeant Pharmaceuticals Intl's management team includes the folowing people:
- Mr. Joseph C. Papa, CEO & Chairman (Age 63)
- Mr. Paul S. Herendeen, Exec. VP & CFO (Age 62)
- Ms. Christina M. Ackermann, Exec. VP & Gen. Counsel (Age 53)
- Mr. Thomas J. Appio, Exec. VP & Group Chairman of International (Age 56)
- Mr. William D. Humphries, Exec. VP & Group Chairman of Dermatology (Age 52)
How do I buy shares of Valeant Pharmaceuticals Intl?
Shares of VRX and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Valeant Pharmaceuticals Intl's official website?
How can I contact Valeant Pharmaceuticals Intl?
Valeant Pharmaceuticals Intl's mailing address is 2150 Saint-Elzear Blvd W, LAVAL, QC H7L 4A8, Canada. The specialty pharmaceutical company can be reached via phone at +1-514-7446792.
MarketBeat Community Rating for Valeant Pharmaceuticals Intl (TSE VRX)
MarketBeat's community ratings are surveys of what our community members think about Valeant Pharmaceuticals Intl and other stocks. Vote "Outperform" if you believe VRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
